Evoke Pharma (NASDAQ:EVOK)

CAPS Rating: 1 out of 5

Caps

How do you think EVOK will perform against the market?

Add Stock to CAPS Watchlist

All Players

9 Outperform
9 Underperform
 

All-Star Players

2 Outperform
6 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top EVOK Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.72)
Submitted April 02, 2014

Lots of weaknesses in the Evoke bull thesis - late stage development is predicated on post hoc analysis of a failed phase IIb trial, orally dissolving metoclopramide seems to have been a commercial failure, and the low float stock is susceptible to… More

zzlangerhans (99.72)
Submitted November 23, 2016

I used to enter red thumbs on crappy microcap biopharmas and then close them once I had ten points or so. I wanted the accuracy point and I was afraid that something would happen to cause the stock to go up 1000% KaloBios style while I wasn't… More

EVOK VS S&P 500 (SPY)

EVOK Summary

Recent Community Commentary

Read the most recent pitches from players about EVOK.

Recs

2
Member Avatar zzlangerhans (99.72) Submitted: 11/23/2016 10:49:56 AM : Underperform Start Price: $1.93 EVOK Score: +7.05

I used to enter red thumbs on crappy microcap biopharmas and then close them once I had ten points or so. I wanted the accuracy point and I was afraid that something would happen to cause the stock to go up 1000% KaloBios style while I wasn't watching. Now I've decided to just leave those red thumbs on since I'm losing more gains from closing them too early than I'm saving on the few that blow up. I think Evoke is a fairly safe bet for eventual low pennies, although the shell game might save them from ultimate bankruptcy.

Evoke's only drug EVK-001 for gastroparesis has failed all late stage trials, the original phase IIb and recently the phase III based on the BS post hoc subset from the phase IIb. The market crushed the stock, but not down to the level it should have, and management immediately took advantage of this by raising 13M from RDO's. Now there's 10M in the kitty which will keep the lights on for another year. Meanwhile management is justifying their existence by blathering about submitting an NDA for EVK-001 despite the failure of all trials. Good luck with that. A couple of months ago the company dropped a nonsensical PR about a "positive" preclinical pre-NDA meeting with the FDA. The only important word there is preclinical. The meeting was purely about CMC and other non-clinical sections of a putative NDA, and the FDA was probably represented by an intern. The company will supposedly meet with the FDA again about the clinical component of an NDA, and I'm guessing that won't go as well. No word yet about the timing of that meeting.

I won't be shorting Evoke because the share count is too low and I don't want to get screwed by any hedge fund games. I probably won't look at the stock again until the share price is under a quarter.

Recs

0
Member Avatar DeathStock (96.87) Submitted: 7/28/2016 2:32:59 PM : Outperform Start Price: $3.22 EVOK Score: -57.76

2016 AQXP? LET US FIND OUT WITH THIS $29 MILLION MARKET CAP GEM.

Recs

0
Member Avatar MMCapitalMgmt (99.93) Submitted: 7/12/2016 4:38:22 PM : Underperform Start Price: $10.30 EVOK Score: +108.40

Down she goes!

Leaderboard

Find the members with the highest scoring picks in EVOK.

Score Leader

GabrielSevrs

GabrielSevrs (31.01) Score: +148.03

The Score Leader is the player with the highest score across all their picks in EVOK.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
MMCapitalMgmt 99.93 7/13/2016 Underperform 5Y $10.30 -77.28% +31.12% +108.40 1 Comment
SawFace 28.50 3/24/2015 Underperform NS $7.11 -67.09% +34.31% +101.40 0 Comment
Playa14 < 20 12/15/2016 Outperform 5Y $1.45 +61.38% +24.36% +37.02 0 Comment
Zencyclone 30.17 9/7/2016 Underperform 5Y $2.13 +9.86% +29.15% +19.29 0 Comment
zzlangerhans 99.72 11/23/2016 Underperform 1Y $1.93 +21.24% +28.30% +7.05 1 Comment
Bigeric42 99.94 11/23/2016 Underperform 5Y $1.93 +21.49% +28.32% +6.84 0 Comment
drugtrader 92.53 12/21/2017 Underperform 5Y $2.25 +4.00% +5.33% +1.32 0 Comment
warrenout2 75.45 11/14/2016 Underperform 5Y $1.65 +41.82% +30.16% -11.66 0 Comment
warrenout 99.39 11/3/2016 Underperform 5Y $1.60 +46.25% +34.52% -11.73 0 Comment
thehammer01 95.72 11/30/2016 Underperform 5Y $1.60 +46.25% +27.99% -18.26 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EVOK.

Featured Broker Partners


Advertisement